Why the study?
Current literature shows a paucity of data on the effectiveness of cytokine absorption hemofiltration and VA-ECMO for COVID-19-induced fulminant myocarditis.
Does cytokine-adsorbing hemofilter CVVH and VA-ECMO improve outcomes in a child with COVID-19-induced fulminant myocarditis?
Does cytokine-adsorbing hemofilter CVVH and VA-ECMO improve outcomes in a child with COVID-19-induced fulminant myocarditis?
Cytokine-adsorbing hemofilter CVVH and VA-ECMO may be effective treatment modalities in managing SARS-CoV-2-induced fulminant myocarditis in children.
Answers are grounded in this paper and cite their sources.
Supports combined cytokine hemofiltration and VA-ECMO in refractory cases; leaves open confirmation via prospective trials.
Background: Indirect cardiomyocyte damage-related hyperinflammatory response is one of the key mechanisms in COVID-19-induced fulminant myocarditis. In addition to the clinical benefit of using cytokines absorption hemofiltration, the effectiveness of instituting veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support for cardiac compromise has been reported. However, current literature enunciates a paucity of available data on the effectiveness of these novel modalities. Case Presentation: hemofilter continuous venovenous hemofiltration (CVVH) and VA-ECMO. The patient made a full recovery without any sequelae. Conclusion: We conclude that the novel highly-absorptive hemofilter CVVH and VA-ECMO may be effective treatment modalities in managing SARS-CoV-2-induced fulminant myocarditis. Our report highlights the need for further well-designed investigations to confirm this extrapolation.
No takes yet. Share an insight, caveat, or question.
Phúc et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: